Adocia falls after Lilly exit | BioPharma Dive
Dive Brief: - Eli Lilly & Co. has rattled Adocia's share price by terminating a December 2014 agreement to develop the French biopharma's ultra-rapid acting insulin for type 1 and type 2 diabetes. - The rights…
Read guide →